Morgan Stanley Biocryst Pharmaceuticals Inc Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Morgan Stanley holds 5,329,679 shares of BCRX stock, worth $44.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,329,679

Previous 2,297,674 131.96%

Holding current value

$44.5 Million

Previous $17.2 Million 177.12%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$6.41 - $11.19 $19.4 Million - $33.9 Million	3,032,005 Added 131.96%	5,329,679 $47.8 Million
Q1 2025 May 15, 2025	BUY	$7.06 - $9.39 $4.46 Million - $5.93 Million	631,942 Added 37.94%	2,297,674 $17.2 Million
Q4 2024 Feb 14, 2025	SELL	$7.03 - $8.43 $515,636 - $618,323	-73,348 Reduced 4.22%	1,665,732 $12.5 Million
Q3 2024 May 14, 2025	BUY	$6.41 - $8.69 $1.03 Million - $1.4 Million	161,131 Added 10.21%	1,739,080 $13.2 Million
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $1.03 Million - $1.4 Million	161,131 Added 10.21%	1,739,080 $13.2 Million
Q2 2024 May 14, 2025	SELL	$4.13 - $6.79 $362,543 - $596,046	-87,783 Reduced 5.27%	1,577,949 $9.75 Million
Q2 2024 Oct 17, 2024	SELL	$4.13 - $6.79 $1.78 Million - $2.92 Million	-430,096 Reduced 21.42%	1,577,949 $9.75 Million
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $1.78 Million - $2.92 Million	-430,096 Reduced 21.42%	1,577,949 $9.75 Million
Q1 2024 Oct 17, 2024	BUY	$4.89 - $7.65 $2.1 Million - $3.29 Million	430,096 Added 27.26%	2,008,045 $10.2 Million
Q1 2024 Aug 16, 2024	SELL	$4.89 - $7.65 $5.52 Million - $8.63 Million	-1,128,643 Reduced 35.98%	2,008,045 $10.2 Million
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $5.52 Million - $8.63 Million	-1,128,643 Reduced 35.98%	2,008,045 $10.2 Million
Q4 2023 Aug 16, 2024	BUY	$4.98 - $6.77 $7.76 Million - $10.6 Million	1,558,739 Added 98.78%	3,136,688 $18.8 Million
Q4 2023 Feb 13, 2024	BUY	$4.98 - $6.77 $6.53 Million - $8.87 Million	1,310,864 Added 71.8%	3,136,688 $18.8 Million
Q3 2023 Nov 15, 2023	BUY	$6.71 - $7.92 $6.41 Million - $7.57 Million	956,027 Added 109.91%	1,825,824 $12.9 Million
Q2 2023 Aug 14, 2023	SELL	$6.96 - $8.81 $5.16 Million - $6.53 Million	-740,873 Reduced 46.0%	869,797 $6.12 Million
Q1 2023 May 15, 2023	BUY	$7.94 - $11.84 $3.61 Million - $5.39 Million	454,939 Added 39.36%	1,610,670 $13.4 Million
Q4 2022 Feb 14, 2023	BUY	$10.5 - $14.2 $2.59 Million - $3.5 Million	246,462 Added 27.11%	1,155,731 $13.3 Million
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $37.4 Million - $51.3 Million	-3,466,300 Reduced 79.22%	909,269 $11.5 Million
Q2 2022 Oct 27, 2022	BUY	$7.89 - $17.88 $28.9 Million - $65.5 Million	3,665,522 Added 516.24%	4,375,569 $46.3 Million
Q2 2022 Aug 15, 2022	BUY	$7.89 - $17.88 $28.9 Million - $65.5 Million	3,665,522 Added 516.24%	4,375,569 $46.3 Million
Q1 2022 Oct 27, 2022	SELL	$11.56 - $19.76 $42.4 Million - $72.4 Million	-3,665,522 Reduced 83.77%	710,047 $11.5 Million
Q1 2022 May 13, 2022	BUY	$11.56 - $19.76 $3.86 Million - $6.59 Million	333,678 Added 88.66%	710,047 $11.5 Million
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $547,909 - $757,663	-49,008 Reduced 11.52%	376,369 $5.21 Million
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $6.04 Million - $7.51 Million	425,377 New	425,377 $6.11 Million

Others Institutions Holding BCRX

# of Institutions

315

Shares Held

202M

Call Options Held

930K

Put Options Held

553K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.55B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account